CAUTION: When reading this news item please be aware that the RejuvenAir System is an Investigational device, limited by United States Federal law to investigational use only. Not for Sale in the United States of America.
CSA Medical Announces Enrollment Milestone in a Mechanism of Action Study utilizing the RejuvenAir® System for COPD Patients with Chronic Bronchitis
This study will provide a scientific rationale for the remodeling response and clinical improvements identified in the feasibility study Boston, MA –November 11, 2020: CSA Medical, Inc., today announced that over half of the subjects in a 32 patient study,...
CSA Medical Announces First Procedure in the SPRAY-CB Pivotal Trial for the Treatment of Chronic Bronchitis
The SPRAY-CB trial marks the first pivotal study of a medical device therapy targeting the underlying cause of Chronic Bronchitis. Boston,MA. – October 22, 2020: CSA Medical Inc., a developer of medical devices advancing the power of liquid nitrogen spray cryotherapy,...
CSA Medical wins CE Mark approval for RejuvenAir System
Published by Mass Device Medical Network CSA Medical announced this week that it won CE Mark approval for its RejuvenAir system for treating chronic obstructive pulmonary disease (COPD) with chronic bronchitis (CB). The RejuvenAir system that is designed to apply...